Rapid de-localization of actin leading edge components with BDM treatment

BACKGROUND: 2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and other actin cytoskeletal processes. Recent reports show that BDM does not inhibit any non-muscle myosins so far...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarrow, Justin C, Lechler, Terry, Li, Rong, Mitchison, Timothy J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165424/
https://www.ncbi.nlm.nih.gov/pubmed/12783627
http://dx.doi.org/10.1186/1471-2121-4-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165424/
https://www.ncbi.nlm.nih.gov/pubmed/12783627
http://dx.doi.org/10.1186/1471-2121-4-5

Ejemplares similares